Matrix metalloproteinase-9 in the culprit coronary artery and myocardial no-reflow

American Journal of the Medical Sciences

Volumn 350, Issue 5, 2015, Pages 352-356

  Dong, Mei ^a   Mu, Nan ^a   Ren, Faxin ^a   Li, Fengli ^a   Zhang, Chuanhuan ^a   Yang, Jun ^a  

^a YANTAI YUHUANGDING HOSPITAL   (China)

Author keywords

Acute myocardial infarction; Inflammation; MMP 9; No reflow

Indexed keywords

CREATINE KINASE MB; GELATINASE B;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD CLOT LYSIS; BLOOD SAMPLING; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY RISK; EMERGENCY CARE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; EXTRACTION CATHETER; FEMALE; HEART CATHETERIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NO REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; ADVERSE EFFECTS; AGED; BLOOD; CORONARY BLOOD VESSEL; ELECTROCARDIOGRAPHY; MIDDLE AGED; MYOCARDIAL INFARCTION; NO-REFLOW PHENOMENON; PATHOLOGY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANGIOPLASTY, BALLOON, CORONARY; CORONARY ANGIOGRAPHY; CORONARY CIRCULATION; CORONARY VESSELS; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MYOCARDIAL INFARCTION; NO-REFLOW PHENOMENON; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 84946560804     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0000000000000559     Document Type: Article

References (33)

1. Reffelmann T, Kloner RA. The no-reflow phenomenon: a basic mechanism of myocardial ischemia and reperfusion. Basic Res Cardiol 2006; 101:359-72.
2. Jaffe R, Dick A, Bradley H. Strauss. Prevention and treatment of microvascular obstruction-related myocardial injury and coronary no-reflow following percutaneous coronary intervention. JACC Cardiovasc Interv 2010;3:695-704.
3. Uzui H, Harpf A, Liu M, et al. Increased expression of membrane type 3-matrix metalloproteinase in human atherosclerotic plaque: role of activated macrophages and inflammatory cytokines. Circulation 2002; 106:3024-30.
4. Muzzio ML, Miksztowicz V, Brites F, et al. Metalloproteases 2 and 9, Lp-PLA(2) and lipoprotein profile in coronary patients. Arch Med Res 2009;40:48-53.
5. Kalela A, Koivu TA, Sisto T, et al. Serum matrix metalloproteinase-9 concentration in angiographically assessed coronary artery disease. Scand J Clin Lab Invest 2002;62:337-42.
6. Kaden JJ, Dempfle CE, Sueselbeck T, et al. Time-dependent changes in the plasma concentration of matrix metalloproteinase 9 after acute myocardial infarction. Cardiology 2003;99:140-4.
7. Funayama H, Ishikawa SE, Kubo N, et al. Close association of regional interleukin-6 levels in the infarct-related culprit coronary artery with restenosis in acute myocardial infarction. Circ J 2006;70:426-9.
8. de Boer MJ, Reiber JH, Suryapranata H, et al. Angiographic findings and catheterisation laboratory events in patients with primary coronary angioplasty or streptokinase therapy for acute myocardial infarction. Eur Heart J 1995;16:1347-55.
9. Gibson CM, Cannon CP, Murphy SA, et al. Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis in Myocardial Infarction (TIMI) Study Group. Circulation 1998;99:1945-50.
10. van't Hof AW, Liem A, Suryapranata H, et al. Angiographic assessment of myocardial reperfusion in patients treated with primary angio-plasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group. Circulation 1998;97:2302-6.
11. Gibson CM, Murphy SA, Morrow DA, et al. Angiographic perfu-sion score: an angiographic variable that integrates both epicardial and tissue level perfusion before and after facilitated percutaneous coronary intervention in acute myocardial infarction. Am Heart J 2004; 148:336-240.
12. Pasterkamp G, Schoneveld AH, Hijnen DJ, et al. Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery. Atherosclerosis 2009;150:245-53.
13. Kai H, Ikeda H, Yasukawa H, et al. Peripheral blood levels of matrix metalloproteases-2 and-9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998;32:368-72.
14. Blankenberg S, Rupprecht HJ, Poirier O, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003;107:1579-85.
15. Jaffe R, Charron T, Puley G, et al. Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention. Circulation 2008;117:3152-6.
16. Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation 2002; 105:656-62.
17. Brauer PR. MMPs: role in cardiovascular development and disease. Front Biosci 2006;11:447-78.
18. Kaartinen M, van der Wal AC, van der Loos CM, et al. Mast cell infiltration in acute coronary syndromes: implications for plaque rupture. J Am Coll Cardiol 1988;32:606-12.
19. Etoh T, Joffs C, Deschamps AM, et al. Myocardial and interstitial matrix metalloproteinase activity after acute myocardial infarction in pigs. Am J Physiol Heart Circ Physiol 2001;281:987-94.
20. Cleutjens JP, Kandala JC, Guarda E, et al. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol 1995;27:1281-92.
21. Kowluru RA, Mohammad G, Dos Santos JM, et al. Abrogation of MMP9 gene protects against the development of retinopathy in diabetic mice by preventing mitochondrial damage. Diabetes 2011;60:3023-33.
22. Kowluru RA, Zhong Q, Santos JM. Matrix metalloproteinases in diabetic retinopathy: potential role of MMP-9. Expert Opin Investig Drugs 2012;21:797-805.
23. Grant MB, Caballero S, Tarnuzzer RW, et al. Matrix metalloprotei-nase expression in human retinal microvascular cells. Diabetes 1998;47: 1311-7.
24. Kowluru RA. Role of matrix metalloproteinase-9 in the development of diabetic retinopathy and its regulation by HRas. Invest Ophthalmol Vis Sci 2010;51:4320-6.
25. Mohammad G, Kowluru RA. Diabetic retinopathy and signaling mechanism for activation of matrix metalloproteinase-9. J Cell Physiol 2012;227:1052-61.
26. Zhong Q, Kowluru RA. Regulation of matrix metalloproteinase-9 by epigenetic modifications and the development of diabetic retinopathy. Diabetes 2013;62:2559-68.
27. Ørn S, Manhenke C, Ueland T, et al. C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction. Eur Heart J 2009; 30: 1180-6.
28. Guo F, Dong M, Ren F, et al. Association between local interleukin-6 levels and slow flow/microvascular dysfunction. J Thromb Thrombol-ysis 2014;374:475-82.
29. van Lint P, Libert C. Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation. J Leukoc Biol 2007;82:1375-81.
30. Delclaux C, Delacourt C, D'Ortho MP, et al. Role of gelatinase B and elastase in human polymorphonuclear neutrophil migration across basement membrane. Am J Respir Cell Mol Biol 1996;14:288-95.
31. McQuibban GA, Butler GS, Gong JH, et al. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem 2001;276:43503-8.
32. Rahman M, Zhang S, Chew M, et al. Platelet shedding of CD40L is regulated by matrix metalloproteinase-9 in abdominal sepsis. J Thromb Haemost 2013;11:1385-98.
33. Fujiwara T, Saito S, Osanai T, et al. Decreased plasma and cardiac matrix metalloproteinase activities in patients with coronary artery disease and treated with pravastatin. Eur J Pharmacol 2008;594:146-51.